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Objectives The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascu-
lar events in patients with clinically stable coronary disease.
Background The presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary dis-
ease raises the possibility that inhibition of neutrophil function with colchicine may reduce the risk of plaque
instability and thereby improve clinical outcomes in patients with stable coronary disease.
Methods In a clinical trial with a prospective, randomized, observer-blinded endpoint design, 532 patients with stable cor-
onary disease receiving aspirin and/or clopidogrel (93%) and statins (95%) were randomly assigned colchicine
0.5 mg/day or no colchicine and followed for a median of 3 years. The primary outcome was the composite inci-
dence of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke. The pri-
mary analysis was by intention-to-treat.
Results The primary outcome occurred in 15 of 282 patients (5.3%) who received colchicine and 40 of 250 patients
(16.0%) assigned no colchicine (hazard ratio: 0.33; 95% confidence interval [CI] 0.18 to 0.59; p  0.001; num-
ber needed to treat: 11). In a pre-specified secondary on-treatment analysis that excluded 32 patients (11%)
assigned to colchicine who withdrew within 30 days due to intestinal intolerance and a further 7 patients
(2%) who did not start treatment, the primary outcome occurred in 4.5% versus 16.0% (hazard ratio: 0.29;
95% CI: 0.15 to 0.56; p  0.001).
Conclusions Colchicine 0.5 mg/day administered in addition to statins and other standard secondary prevention therapies
appeared effective for the prevention of cardiovascular events in patients with stable coronary disease. (J Am
Coll Cardiol 2013;61:404–10) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.027e
o
F
mDespite routine use of antiplatelet and statin therapy,
patients with coronary disease continue to be at risk of
cardiovascular events, possibly because these treatments fail
to target some of the inflammatory pathways implicated in
the disease. The atherosclerotic wall is subject to injurious
forces that promote plaque instability. The response to
injury within the diseased vessel is dependent on the
architecture and content of atherosclerotic plaques (1,2).
Lipid-rich plaques with a neovascular base are particularly
susceptible to the effect of injury, which may leave them
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o2012, accepted October 23, 2012.vulnerable to neutrophil infiltration (3). Neutrophils that
enter the interstitial space may become activated upon
exposure to the plaque contents, inciting an aggressive
inflammatory response that may accelerate plaque instabil-
ity, increasing the risk of plaque enlargement and rupture
and hence increasing the risk of clinical events (3).
See page 411
This dynamic sequence of events raises the possibility that
inhibition of neutrophil function may lead to a reduction in the
risk of plaque instability and thereby reduction in the risk of
disease progression. Colchicine has anti-inflammatory proper-
ties, including an antitubulin effect that inhibits neutrophil
function (4), and this effect is believed to account for the
fficacy of colchicine in the prevention of acute manifestations
f gout and familial Mediterranean fever (FMF). Patients with
MF receive lifelong colchicine therapy at a dose of 1 to 2
g/day, which is well tolerated (5,6). Although short-term usef low-dose colchicine has been found to have no effect on
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January 29, 2013:404–10 Colchicine in Stable Coronary Diseasestent-related disease (7), no studies have been performed to
etermine whether long-term use of low-dose colchicine can
e tolerated or can reduce the risk of de novo vascular events
aused by disruption of native atherosclerotic plaques in pa-
ients with stable coronary disease.
We therefore conducted a prospective, randomized,
bserver-blinded endpoint (PROBE) trial to determine
hether adding colchicine 0.5 mg/day to standard second-
ry prevention therapies including aspirin and high-dose
tatins reduces the risk of cardiovascular events in patients
ith objectively diagnosed and clinically stable coronary
isease.
ethods
tudy conduct and design. The LoDoCo (Low-Dose Col-
chicine) trial was conducted under the auspices of the Heart
Research Institute of Western Australia. It was designed by the
principal investigators, registered with the Australian Clinical
Trial Registry (ACTRN 12610000293066), and received eth-
ics approval from the Human Research Ethics Committee at
Sir Charles Gairdner Hospital, Perth, Western Australia in
July 2008. There was no external funding source.
We employed a PROBE design (8). Eligible consenting
patients with established coronary disease presenting for
routine clinical review were randomized to receive colchi-
cine 0.5 mg/day or no colchicine without any other changes
to their medical therapy. All outcomes were evaluated by an
experienced adjudicator blinded to the treatment allocation.
Study size and eligibility. The study population was
planned to include 250 patients randomized to the control
group and 250 patients randomized to treatment who were
tolerant of colchicine for at least 4 weeks after the date of
their randomization.
Patients were eligible for inclusion if they met each of the
following criteria: 1) angiographically proven coronary disease;
2) age 35 to 85 years; 3) clinically stable for at least 6 months;
4) no major competing comorbidities or contraindication to
colchicine therapy; 5) considered to be compliant with therapy
and attending routine cardiology follow-up appointments; and
6) willing to provide consent and be randomized into the study.
Patients with a history of bypass surgery were only eligible if
they had undergone bypass surgery more than 10 years before,
had angiographic evidence of graft failure, or had undergone
stenting since their bypass surgery. All patients signed in-
formed consent before randomization.
Randomization. The randomization sequence was com-
puter generated, concealed from the investigators at all
times, and managed by a research assistant who had no
involvement in the evaluation or management of study
patients. Once the assistant received the consent form, the
patients’ demographic data were entered into the database,
and the investigators and patients were advised in writing of
the treatment group to which the patient had been assigned.
Despite use of the lowest dose of colchicine available, it
was anticipated that a number of patients would withdrawfrom therapy early after random-
ization because of gastrointesti-
nal side effects. To ensure that
the requisite number of patients
in the treatment arm were actu-
ally tolerant of treatment, the
protocol allowed for the research
assistant to assign a newly re-
cruited patient to treatment if a
patient discontinued colchicine
because of side effects in the first
month. Patients who were intol-
erant of therapy remained in the
study, were followed in the usual
manner, and were included in the
primary intent-to-treat analysis.
Intervention. Patients randomized to active treatment were
given a prescription for colchicine 0.5 mg daily by their
referring cardiologist. The drug was dispensed by their usual
chemist, and if requested, patients were reimbursed for the cost
of these prescriptions. All other treatments were continued as
usual.
Follow-up and definition of clinical outcomes. Patient
compliance with treatment and outcome data were collected
at routine follow-up visits and at the time of any unplanned
hospital admissions.
Acute coronary syndrome (ACS) was defined as either: 1)
acute myocardial infarction (AMI), as evidenced by acute
ischemic chest pain associated with a rise in serum troponin
above the upper limit of normal (9); or 2) unstable angina
(UA), as evidenced by a recent acceleration of angina
unassociated with a rise in serum troponin but associated
with angiographic evidence of a change in the patient’s
coronary anatomy (UA Braunwald classification types IB
and IIB) (10). ACS was characterized as being stent related
if there was evidence of significant in-stent stenosis or acute
stent thrombosis. Out-of-hospital cardiac arrest was defined
as: 1) a sudden death as evidenced on the patient’s death
certificate; or 2) a nonfatal out-of-hospital cardiac arrest,
defined as a recovery from sudden collapse associated with
documented asystole, ventricular tachycardia, or ventricular
fibrillation. Noncardioembolic ischemic stroke was defined
as computed tomography—or magnetic resonance imag-
ing—proven ischemic stroke judged by the treating neurol-
ogist as not being due to atrial fibrillation or intracranial
hemorrhage. The primary efficacy outcome was the composite of
ACS, fatal or nonfatal out-of-hospital cardiac arrest, or noncar-
dioembolic ischemic stroke. Secondary outcomes were individual
components of the primary outcome and the components of ACS
unrelated to stent disease.
Timelines. The pre-specified study duration was a mini-
mum follow-up of 2 years in all patients. Accordingly, the
study was closed on May 31, 2012. During May, all living
patients were contacted by phone to collect compliance and
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AMI  acute myocardial
infarction
FMF  familial
Mediterranean fever
HR  hazard ratio
MI  myocardial infarction
PROBE  prospective,
randomized, observer-
blinded endpoint
UA  unstable anginaoutcome data from the last date of follow-up. Final outcome
s
D
d
t
d
1
p
o
i
t
t
p
b
t
d
w
a
a
a
t
o
p
d
b
a
fi
m
c
R
S
9
o
b
e
(
r
t
i
s
(
d
o
3
i
w
406 Nidorf et al. JACC Vol. 61, No. 4, 2013
Colchicine in Stable Coronary Disease January 29, 2013:404–10data were available for all patients, and no patients were lost
to follow-up.
Statistical power. Assuming that the control group had a
combined event rate (ACS, out-of-hospital cardiac arrest, or
noncardioembolic ischemic stroke) of 8% (11), an accrual
interval of 2 years, and a follow-up after the accrual interval
of 2 years, the planned sample size provided80% power to
detect a hazard ratio (HR) of 0.50 based on a 2-sided
ignificance level of 5%.
ata analysis. Summary statistics, including mean and stan-
ard deviation, were calculated for all baseline characteristics by
reatment arm. All time-to-event outcomes were calculated in
ays by subtracting the date of randomization from either the:
) date of event or death; or 2) trial termination date for those
atients not experiencing the defined event.
As pre-specified, the primary efficacy analysis was based
n the intent-to-treat principle. The intent-to-treat analysis
ncluded all randomized patients and all events during the
ime from randomization to trial termination. The trial
ermination date was fixed as May 31, 2012. A secondary
re-specified on-treatment analysis was also performed,
ased on patients who were both tolerant and compliant to
herapy beyond the first month of randomization. All events
uring the time from randomization until noncompliance
ith the colchicine treatment regime were included in this
nalysis.
The time to first event for all outcomes is presented using
Kaplan-Meier plot. The primary efficacy outcome was
Figure 1 The CONSORT Flow Diagram
The CONSORT diagram showing the number of participants who were randomized,nalyzed using a Cox proportional hazards model including areatment group coded as control or colchicine. The sec-
ndary outcomes were analyzed similarly. In addition, the
rimary analysis was stratified by sex, age, diagnosis of
iabetes, past myocardial infarction (MI), UA, coronary
ypass surgery, coronary angioplasty, and therapy with
spirin, clopidogrel, or both; high-dose statin therapy (de-
ned as a dose of statin equivalent to atorvastatin 40 mg or
ore); beta-blockers; calcium blockers; and angiotensin-
onverting enzyme inhibitors.
esults
tudy population. Between August 2008 and May 2010,
01 patients with stable coronary disease attending routine
utpatient cardiology appointments were assessed for eligi-
ility for the study. Of these, 297 (33%) did not meet the
ntry criteria, 72 (8%) declined to participate, and 532
59%) were enrolled into the study, 250 of whom were
andomized to the control group and 282 to treatment. Of
hose randomized to treatment, 32 (11%) reported early
ntolerance due to gastrointestinal side effects and 7 patients
ubsequently reported that they chose to not start therapy
Fig. 1). All 532 randomized patients were followed for the
uration of the study period, which ranged from a minimum
f 24 to a maximum of 44 months. Median follow-up was
6 months. Baseline characteristics according to random-
zed treatment group are shown in Table 1. Both groups
ere well matched for important clinical characteristics,
follow-up, and included in the primary data analysis.lost tolthough more patients in the colchicine group were taking
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January 29, 2013:404–10 Colchicine in Stable Coronary Diseasecalcium channel blockers and fewer were on beta-blocker
therapy. Almost all patients in each group were on anti-
platelet therapy and high-dose statin therapy.
Late discontinuations. Thirty patients ceased colchicine
therapy after a mean period of 2.36 years. Therapy was
ceased due to an unrelated intercurrent illness in 11 patients,
by choice in 5, and for a variety of possible drug-related
effects in 14 patients (4.9%) as described in Table 2.
utcomes. A primary outcome occurred in 55 of 532
atients, including 15 of 282 patients (5.3%) assigned to
olchicine treatment and 40 of 250 patients (16%) assigned
o the control group (HR: 0.33; 95% confidence interval
CI] 0.18 to 0.59; p  0.001; number needed to treat: 11).
sensitivity analysis was performed for the primary out-
ome and adjusted for the usage of calcium channel blockers
nd beta-blocker therapy. These results were consistent with
he primary analysis.
The time to first clinical event in each group by treatment
s shown in Figure 2. The effect of colchicine on the primary
utcome was evident early, and the benefits of colchicine
Study PopulationTable 1 Study Population
Control Treatment
Total 250 282
Mean age, yrs 67 9.2 66 9.6
Male 222 (89) 251 (89)
Diabetes 69 (28) 92 (33)
Smoker 14 (6) 10 (4)
Past AMI or UA 61 (24) 64 (23)
CABG 39 (16) 62 (22)
PTCA 138 (55) 169 (60)
Aspirin and/or clopidogrel 235 (94) 262 (93)
DAPT 24 (10) 38 (13)
High-dose statin 235 (94) 271 (96)
Beta-blocker* 178 (71) 176 (62)
Calcium channel blocker† 25 (10) 52 (18)
ACE inhibitor 150 (60) 155 (55)
Values are n, mean  SD, or n (%). *p  0.05. †p  0.01 for the comparison of the distribution
between treatment and control.
ACE  angiotensin-converting enzyme; AMI  acute myocardial infarction; CABG  coronary
artery bypass surgery; DAPT  dual antiplatelet therapy (aspirin and clopidogrel); PTCA 
percutaneous coronary angioplasty; UA  unstable angina.
Withdrawals From TherapyTable 2 Withdrawals From Therapy
Early withdrawals 32 (11)
Late withdrawals* 30 (11)
Unrelated intercurrent illness 11 (3.9)
Patient choice 5 (1.8)
Perceived side effects
Intestinal upset 7 (2.5)
Myalgia 2 (0.90)
Myositis 1 (0.5)
Rash 1 (0.5)
Alopecia 1 (0.5)
Itch 1 (0.5)
Peripheral neuritis 1 (0.5)Values are n (%). *Withdrawals after 30 days; average time to withdrawal was 2.36 years.ontinued to accrue throughout the follow-up period. Re-
ults of the primary analysis were consistent in all subgroups
xamined (Fig. 3). There was no evidence of differential
reatment effects based on any of the clinical or therapeutic
ariables.
Figure 2 Freedom From the Primary Outcome
Freedom from the primary outcome (acute coronary syndrome, out-of-hospital
cardiac arrest, or noncardioembolic ischemic stroke) by treatment. CI  confi-
dence interval; HR  hazard ratio.
Figure 3 Forest Plot
The hazard ratios and 95% CI of the primary outcome in subgroups defined by
patient demographics, past medical history, and concomitant treatments.
ACE  angiotensin-converting enzyme inhibitor; AMI  acute myocardial infarc-
tion; BB  beta-blocker; CABG  coronary artery bypass graft; DAPT  dual
antiplatelet therapy; PTCA  percutaneous coronary angioplasty; UA  unsta-
ble angina; other abbreviations as in Figure 2.
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Colchicine in Stable Coronary Disease January 29, 2013:404–10The reduction in the primary outcome was largely driven
by the reduction in the number of patients presenting with
ACS (13 of 282 [4.6%] vs. 34 of 250 [13.4%]; HR: 0.33;
95% CI: 0.18 to 0.63; p  0.001). Out-of-hospital cardiac
rrest and noncardioembolic ischemic stroke were infre-
uent, but their numbers were also reduced in the treatment
roup (Table 3).
Of the 47 patients who presented with ACS, the event
as stent related in 8 (17%; 2 in each group had evidence of
cute stent thrombosis, and 2 in each group had evidence of
ignificant in-stent stenosis). Further analysis confirmed
hat patients randomized to treatment were less likely to
resent with ACS unrelated to stent disease (9 of 282
3.2%] vs. 30 of 250 [12%]; HR: 0.26; 95% CI: 0.12 to 0.55;
 0.001), be it associated with AMI (4 of 282 [1.4%] vs.
4 of 250 [5.6%]; HR: 0.25; 95% CI: 0.08 to 0.76; p 
.014) or UA (5 of 282 [1.8%] vs. 16 of 250 [6.4%]; HR:
.27; 95% CI: 0.10 to 0.75; p  0.011) (Fig. 4, Table 3).
Of 39 patients randomized to treatment who did not
eceive therapy beyond the first month because of early
ntolerance or noncompliance, 4 (10%) presented with ACS
ue to acute stent thrombosis (n  1) and UA (n  3).
atients who were both compliant and tolerant to therapy
eyond the first month of randomization had significantly
ewer events than the control patients (11 of 243 [4.5%] vs.
0 of 250 [16%]; HR: 0.29; 95% CI: 0.15 to 0.56; p 
.001). The results of all on-treatment analyses were consistent
ith those based on intent-to-treat analyses (Table 4).
Ten patients in the control group died compared with 4
atients in the colchicine group. Of the 10 control patients,
died of presumed cardiac cause, 2 following an out-of-
ospital cardiac arrest, 2 from cardiogenic shock following
MI, and 1 following bypass surgery. All 4 patients in the
olchicine group died of noncardiac causes.
iscussion
he LoDoCo trial demonstrated that the addition of
olchicine 0.5 mg/day to standard therapy in patients with
table coronary disease significantly reduced the risk of a
Primary Outcome and Its ComponentsTable 3 Primary Outcome and Its Componen
Control (n  250)
Primary outcome 40 (16)
Components of primary outcome
Acute coronary syndrome 34 (13.6)
OOH cardiac arrest 2 (0.8)
Noncardioembolic stroke 4 (1.6)
Components of ACS
Stent-related 4 (1.6)
Nonstent-related 30 (12)
Nonstent-related AMI 14 (5.6)
Nonstent-related UA 16 (12)
Values are n (%). *Nonfatal.
ACS  acute coronary syndrome; NS  nonsignificant; OOH  outardiovascular event, including ACS, out-of-hospital car- aiac arrest, and noncardioembolic ischemic stroke. The
enefits of colchicine were achieved on a background of
idespread use of effective secondary prevention strategies,
ncluding high-dose statins, as evidenced by the low event
ate in the control group (11). The effect of adding colchi-
ine became evident early, continued to accrue over time,
nd was largely driven by a reduction in ACS unrelated to
tent disease.
These results are important because they suggest that
olchicine, in contrast to its apparent lack of effect in the
revention of stent-related disease (7), may have a role in
he prevention of cardiovascular events caused by instability
f native atherosclerotic plaques in patients with stable
oronary disease, possibly by inhibiting an inflammatory
athway that has been indentified in unstable native coro-
ary plaques (3).
The presence of activated neutrophils in the plaques of
atients with unstable coronary syndromes (3) suggested
hat they may play a key role in the transformation of a
table, to an unstable plaque. Although the mechanism of
enefit of colchicine was not the subject of this study, the
rug is known to have protean effects that may be respon-
ible for the improved clinical outcome of patients observed
n this study, the best documented of which is the inhibition
f neutrophil chemotaxis, ingress, and activation within a
roinflammatory environment (12) such as may exist in an
nstable plaque.
Indirect support for a beneficial effect of colchicine on
ardiovascular disease comes from retrospective observations
hat continuous use of colchicine was associated with a
ower than expected risk of AMI in patients with FMF (13)
nd gout (14), and the demonstration that low-dose colchi-
ine can reduce levels of high-sensitivity C-reactive protein
n patients with stable coronary disease (15).
Although most physicians are familiar with the short-
erm use of colchicine from its widespread use in gout and
ericarditis (16), few will have prescribed it continuously to
heir patients. However, the long-term use of colchicine, at
oses of 1 to 2 mg/day, has been well documented to be safe
reatment (n  282) HR (95% CI) p Value
15 (5.3) 0.33 (0.18–0.59) 0.001
13 (4.6) 0.33 (0.18–0.63) 0.001
1 (0.35)* 0.47 (0.04–5.15) 0.534
1 (0.35) 0.23 (0.03–2.03) 0.184
4 (1.4) NS
9 (3.2) 0.26 (0.12–0.55) 0.001
4 (1.6) 0.25 (0.08–0.76) 0.014
5 (2.4) 0.27 (0.10–0.75) 0.011
ital; other abbreviations as in Table 1.ts
Tnd reasonably well tolerated in patients with FMF (17).
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January 29, 2013:404–10 Colchicine in Stable Coronary DiseaseIn this study, despite use of the lowest available dose of
colchicine, 11% of patients withdrew from therapy early due
to intestinal intolerance, and a further 5% ceased therapy
late due to a range of possible side effects, indicating that
Figure 4 Freedom From Acute Coronary Syndrome
Freedom from acute coronary syndrome (ACS) and components of this outcome (A
Primary Outcome and Its Components (On-TreatTable 4 Primary Outcome and Its Componen
Control (n  250)
Primary outcome 40 (16)
Components of primary outcome
Acute coronary syndrome 34 (13.6)
OOH cardiac arrest 2 (0.8)
Noncardioembolic stroke 4 (1.6)
Components of ACS
Stent-related 4 (1.6)
Nonstent-related 30 (12)
Nonstent-related AMI 14 (5.6)
Nonstent-related UA 16 (12)Values are n (%). *Nonfatal.
Abbreviations as in Tables 1 and 3.widespread use of the drug may be limited by its side effects.
In this regard, it is important to appreciate that combining
colchicine with statin therapy has been reported to increase
the risk of myalgia and rarely acute rhabdomyolysis in
d UA) unrelated to stent disease. Abbreviations as in Figures 2 and 3.
Analysis)n-Treatment Analysis)
tment (n  243) HR (95% CI) p Value
11 (5.3) 0.29 (0.15–0.56) 0.001
9 (4.6) 0.28 (0.13–0.58) 0.001
1 (0.35)* 0.55 (0.05–6.03) 0.622
1 (0.35) 0.27 (0.03–2.42) 0.242
3 (1.4) NS
6 (3.2) 0.21 (0.09–0.50) 0.001
4 (1.6) 0.30 (0.10–0.91) 0.033
2 (2.4) 0.13 (0.03–0.57) 0.007MI anmentts (O
Trea
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Colchicine in Stable Coronary Disease January 29, 2013:404–10patients with renal impairment (18). Further, because col-
chicine has a narrow therapeutic index, extreme care must
be taken to avoid accidental overdoses, which may be fatal.
Hence, patients receiving regular colchicine therapy require
close clinical supervision.
Despite these caveats, colchicine may be an attractive
therapy for secondary prevention of cardiovascular events
because it is simple to use and inexpensive, it appears to be
highly effective, and long-term use rarely leads to any major
irreversible long-term toxicity. Before the drug is adopted
clinically, however, it would be important for the findings of
this hypothesis-generating study to be confirmed in larger
studies of patients with coronary atherosclerosis.
Study limitations. This study has a number of limitations.
The use of a PROBE design had the advantages of
convenience, reduced cost, and fewer safety concerns; how-
ever, it may be subject to outcome ascertainment and
reporting bias. Although the decision to allow the research
assistant to assign additional patients to treatment if a
patient reported early intolerance to therapy had the poten-
tial to introduce bias to the randomization process, this was
largely avoided because at all times, the investigators re-
mained unaware as to whether a newly recruited patient
would be randomized to colchicine or control or would be
replacing an intolerant patient. Further, because the treat-
ment groups remained well matched at baseline, the primary
events occurred over a 3- to 4-year period after randomiza-
tion, all randomized patients were followed and included in
the primary intent-to-treat analysis, and the results are
extremely robust, it is extremely unlikely that our approach
materially affected the results or conclusions.
The results of this study were almost entirely driven by an
effect of colchicine on nonfatal cardiovascular events that
disrupt patients’ lives, portend their prognosis, and are
responsible for a significant cost burden on the community.
Although a favorable trend toward improved mortality was
demonstrated, much larger studies are required to confirm
whether colchicine may actually reduce the risk of fatal
cardiac events. It would be of special interest to examine the
value of initiating colchicine in patients recently hospital-
ized for ACS because they remain at particularly high risk of
recurrent events for several months due to disruption of
both culprit and nonculprit plaques (19).
Conclusions
In summary, colchicine 0.5 mg/day given in addition to
high-dose statins and other standard secondary prevention
therapies appeared effective for the prevention of cardiovas-
cular events in patients with stable coronary disease. The
major implications of these findings are that it may be
possible to reduce the risk of cardiovascular events in
patients with stable coronary disease by targeting an inflam-
matory pathway that has been identified in native unstableatherosclerotic plaques using a low dose of colchicine. Despite
the problems with early intolerance, it would appear that
colchicine is a worthy candidate drug for future secondary
prevention trials in patients with stable coronary disease.
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